Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in japan

Nephron - Clinical Practice

Volumn 115, Issue 1, 2010, Pages

  Itabashi, Mitsuyo ^a   Takei, Takashi ^a   Yabuki, Yasuko ^b   Suzuki, Hitoe ^b   Ando, Minoru ^b   Akamatsu, Mayuko ^c   Yamazaki, Mayuko ^c   Mitobe, Michihiro ^c   Watanabe, Yoshihiko ^d   Mochizuki, Takahiro ^d   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c Saiseikai Kurihashi Hospital   (Japan)

^d KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Birmingham Vasculitis Activity Score; Infection; Myeloperoxidase anti neutrophil cytoplasmic antibody; Prognosis; Vasculitis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTICLE; CAUSE OF DEATH; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HEART DISEASE; HEMATURIA; HUMAN; INFECTION; JAPAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; SCORING SYSTEM; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 76749138045     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000286346     Document Type: Article

References (27)

1. Hoffman GS, Specks U: Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41: 1521-1537. (Pubitemid 28459910)
2. Bosch X, Guilabert A, Font J: Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-418. (Pubitemid 44108124)
3. Guillevin L, Durand-Gasselin B, Cevallos R, et al: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-430. (Pubitemid 29136088)
4. Falk RJ, Jennette JC: Thoughts about the classification of small vessel vasculitis. J Nephrol 2004; 17: S3-S9. (Pubitemid 44178733)
5. Boomsma MM, Stegeman CA, van der Leij MJ, et al: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-2033.
6. Tervaert JW, Huitema MG, Hene RJ, et al: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711.
7. Tervaert JW, van der Woude FJ, Fauci AS, et al: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-2465. (Pubitemid 19283202)
8. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA: Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006; 45: 724-729.
9. Luqmani RA, Bacon PA, Beaman M, et al: Classical versus non-renal Wegener's granulomatosis. Q J Med 1994; 87: 161-167. (Pubitemid 24075773)
10. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Vatten L, Jorstad S: Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15: 611-618. (Pubitemid 30242977)
11. Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E: Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991; 35: 139-147.
12. Uezono S, Sato Y, Hara S, et al: Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture. Intern Med 2007; 46: 815-822. (Pubitemid 47261662)
13. Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192. (Pubitemid 24065492)
14. Imai E, Matsuo S, Makino H, et al: Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 2008; 31: 1101-1107.
15. Luqmani RA, Bacon PA, Moots RJ, et al: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-678.
16. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD: ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403-1411. (Pubitemid 38786731)
17. Vassallo M, Shepherd RJ, Iqbal P, Feehally J: Agerelated variations in presentation and outcome in Wegener's Granulomatosis. J R Coll Physicians 1997; 31: 396-400. (Pubitemid 27363965)
18. Slot MC, Cohen Tervaert, Franssen CF: Renal Survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-677. (Pubitemid 36126814)
19. Koldingsnes W, Nossent H: Epidemiology of Wegener's granulomatosis in Northern Norway. Arthritis Rheum 2000; 43: 2481-2487.
20. Green H, Paul M, Vidal L, Leibovici L: Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052-1059. (Pubitemid 47357136)
21. Terrier B, Saadoun D, Sène D, et al: Anti-myeloperoxidase antibodies are a useful marker of disease activity in ANCA-associated vasculitides. Ann Rheum Dis 2008; in press.
22. Jayne D, Rasmussen N, Andrassy K, et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44. (Pubitemid 36765101)
23. Hirayama K, Kobayashi M, Hashimoto Y, et al: Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis 2004; 44: 57-63. (Pubitemid 38880927)
24. Gayraud M, Guillevin L, le Toumelin P, et al: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-675. (Pubitemid 32234626)
25. Martinez V, Cohen P, Pagnoux C, et al: Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58: 308-317.
26. Schwenger V, Sis J, Breitbart A, Andrassy K: CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998; 26: 274-276. (Pubitemid 28466499)
27. Kaysen GA, Don BR: Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int 2003; 84: S94-S97.